Synopsis
Recognise autonomous nodular hyperthyroidism, define structural and functional risk, and choose durable radioiodine or surgical treatment while controlling cardiovascular consequences.
- Toxic multinodular goitre contains several autonomously functioning areas, whereas toxic adenoma is a single dominant autonomous nodule suppressing the surrounding gland.
- Both become more common with age and often present gradually through atrial fibrillation, heart failure, weight loss or osteoporosis rather than classic Graves features.
- Biochemistry shows suppressed TSH with raised free T4 and/or free T3; T3-predominant disease is particularly common in nodular autonomy.
- An irregular multinodular gland suggests toxic multinodular goitre, while a solitary nodule suggests adenoma, but palpation alone cannot establish function or cancer risk.
- TRAb is usually negative and scintigraphy demonstrates patchy multiple uptake or one focal hot nodule with suppression of background tissue.
- NICE generally favours radioiodine as first-line definitive treatment for toxic multinodular goitre when suitable; surgery is preferred for compression, suspected malignancy or unsuitable radioiodine.
- For a toxic adenoma, radioiodine or hemithyroidectomy can be definitive, selected by nodule anatomy, patient priorities, surgical risk and local expertise.
- Antithyroid medicine controls hormone synthesis but autonomy rarely enters durable remission, so it is usually a bridge or lifelong treatment only when definitive options are unsuitable.
- A confirmed hyperfunctioning hot nodule is rarely malignant and is not routinely aspirated unless ultrasound or clinical features create a separate concern.
- Pregnancy and breastfeeding exclude radioiodine and need a specialist plan; iodine contrast can aggravate autonomy and affect later radionuclide treatment timing.
Key red flags
New atrial fibrillation, worsening angina, exertional dyspnoea, ankle swelling or high-output failure may be the main manifestation and deserves urgent cardiovascular assessment according to stability.
Dysphagia, voice change, cough, positional dyspnoea, stridor, facial congestion or distended neck veins suggests oesophageal, recurrent-laryngeal, tracheal or mediastinal compression and strengthens the surgical pathway.
Investigation priorities
Confirm overt or subclinical hormone excess and identify T3 predominance.
Management branches
Suppressed TSH occurs with a palpable nodule or multinodular gland.
- Measure free T4 and free T3, examine the neck and nodes, and review Graves signs, iodine exposure, amiodarone and pregnancy possibility.
- Use TRAb and endocrinology-directed scintigraphy to establish autonomy; obtain ultrasound for structural characterisation when the nodule or goitre meets a clinical indication.
- Assess cardiac rhythm, heart failure, bone and compression risk before deciding how quickly hormone control and definitive treatment are needed.
Key medicines
Carbimazole for autonomous hyperthyroidismChoose a BNF-listed initial total commonly within 15 to 40 mg daily according to free-hormone elevation, then titrate through endocrinology while definitive treatment is planned.Check baseline blood count and liver tests. Stop for fever, sore throat or mouth ulcers pending urgent count; address pregnancy, contraception, hepatic symptoms and pancreatitis under current MHRA advice.
Beta blocker for nodular thyrotoxic symptomsUse an individual BNF-checked oral beta-blocker regimen, for example propranolol 10 to 40 mg three or four times daily when appropriate, titrated to pulse and tolerance.Check for asthma, bradycardia, heart block, hypotension and low-output failure. Rate control does not replace anticoagulation assessment or treatment of decompensated heart failure.